BPC-157 vs TB-500
Last updated: October 2026
The two most popular healing peptides, head to head. In animal studies, BPC-157 is best known for gut and tendon repair, while thymosin beta-4 (TB-500's parent protein) is studied for cardiac repair and wound healing. Partly different mechanisms, and frequently stacked together.
(Knee-Pain Chart Review)
(See Sources)
(Neither Approved)
Track your vials and inventory on paper
Printable vial and inventory sheets for your own research records. Every value is entered by you. Free to build and preview; $5/month to unlock printing.
Side-by-Side: Key Facts
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Full Name | Body Protection Compound-157 | Thymosin Beta-4 Fragment |
| Origin | Gastric pentadecapeptide (15 amino acids) | Synthetic fragment of thymosin beta-4 (full Tβ4 is a 43-amino-acid protein) |
| Source | Derived from human gastric juice protein | Derived from thymus gland protein |
| Primary Target | Gut lesions, tendon repair (animal studies) | Cardiac repair, skin and corneal wound healing (animal studies of Tβ4) |
| Mechanism | Angiogenesis, granulation tissue, NO-system interactions | Actin binding, cell migration, angiogenesis, anti-inflammation |
| Dosing | No human dose established in cited studies (animal dosing only) | No human dose established in cited studies |
| Route | SubQ, IM, or Oral | SubQ or IM |
| Oral Stability | Described as a stable peptide; human oral absorption not measured | No oral data in cited studies |
| Side Effects | Not characterized in the cited studies | Not characterized in the cited studies |
| FDA Status | Not approved; placed in FDA Category 2 (Sept 2023); nomination later withdrawn (current FDA list) | Not approved, sold as a research peptide |
| Research Level | Mostly animal studies; 1 human study cited here (PMID 34324435: retrospective chart review of 17 patients with multiple types of knee pain, 16 reached for phone follow-up; 11/12 given BPC-157 alone reported significant improvement). Not the only human work: the cited 2003 tendon paper (PMID 14554208) notes BPC 157 was then in clinical trials for inflammatory bowel disease. | Mostly animal studies of full-length thymosin beta-4; the same knee-pain review also included patients given BPC-157 combined with TB4 |
| Common Stack | Often combined with TB-500 | Often combined with BPC-157 |
Research Supplier
Research peptides from Swiss Chems, our affiliate vendor. Research peptides are unregulated. Check each product's certificate of analysis.
Affiliate links support HighPeptides at no extra cost. Swiss Chems publishes third-party HPLC COAs for selected products (vendor-published, a claim to verify).
Different Pathways, Same Goal: Repair
BPC-157 and TB-500 are thought to promote healing through partly different molecular mechanisms, though both have been linked to new blood vessel formation (angiogenesis) in animal studies. The proposed differences are why they're so commonly stacked.
A 15-amino-acid peptide derived from a protein found in human gastric juice (BPC). In the rat studies cited here, BPC-157 is linked to angiogenesis (new blood vessel formation), granulation tissue formation, and interactions with the nitric oxide (NO) system. A separate rat tendon-fibroblast study (PMID 21030672, not in the reference list below) reports that its effect on fibroblast migration is likely mediated by the FAK-paxillin pathway. Described as a stable peptide in the cited studies; oral bioavailability in humans has not been measured.
A synthetic fragment of thymosin beta-4 (Tβ4), a 43-amino-acid protein naturally produced in the thymus and found in most human cells. In animal and cell studies, Tβ4 binds actin and promotes cell migration, including the mobilization and differentiation of stem/progenitor cells. It also promotes new blood vessel formation (angiogenesis) in rodents and lowered inflammatory cytokine mRNA levels after corneal injury in mice.
Healing Targets Compared
Based on the preclinical studies cited on this page. Ratings are our editorial summary of relative strength of animal-model evidence. No large controlled human trial results are cited for either compound for these indications. TB-500 ratings reflect studies of full-length thymosin beta-4; none of the cited studies tested the TB-500 fragment itself.
Why They're Frequently Combined
BPC-157 and TB-500 are among the most commonly stacked peptides in the research community. The rationale is mechanistic and theoretical: they are thought to act through partly different pathways.
BPC-157 is linked to new blood vessel formation (angiogenesis) and granulation tissue in rat studies. Thymosin beta-4 binds actin to drive cell migration and is also angiogenic in rodent studies, with reduced inflammatory signaling in a mouse corneal model. The theoretical case for stacking is that their mechanisms overlap only partly. No controlled study cited here has tested the combination.
How They're Typically Used
Most of the primary studies cited on this page dosed animals (rats or mice). The one human report cited (PMID 34324435) is a small retrospective chart review of knee-pain patients who had BPC-157, alone or with TB4, injected into the knee. No human dose, frequency, or cycle length for either peptide is established by these sources, and neither has FDA-approved dosing. Always consult a physician.
Side Effects: Limited Data
The studies cited on this page provide little adverse-event or tolerability data for either BPC-157 or TB-500. Side effects mentioned online are anecdotal community reports, not trial data, and long-term safety data in humans is extremely limited for both compounds.
Important context: A lack of reported side effects doesn't mean "proven safe." The side effect data that exists comes primarily from animal studies and community self-reports. Long-term effects, rare adverse events, and drug interactions are essentially unknown. Absence of evidence is not evidence of absence.
Regulatory Status & Availability
Neither peptide is FDA-approved. Both are sold as "research chemicals" (not for human consumption). The regulatory landscape has been shifting, particularly for BPC-157.
FDA crackdown on BPC-157: On September 29, 2023, the FDA moved BPC-157 to Category 2 of its bulk drug substances list, effectively blocking compounding pharmacies from producing it for patients. This was a significant access change: previously many users obtained BPC-157 through compounding pharmacies with a doctor's prescription. Research peptide vendors remain the primary source, but these products are not regulated for human use and purity varies by vendor.
Decision Framework
Based on published research targets. This is not medical advice. Neither compound is approved for human therapeutic use. Many researchers use both simultaneously.
- Gut healing: gastrointestinal lesions and ulcers (animal models)
- Tendon injury (transected rat Achilles tendon model)
- Oral route: sometimes used for gut targets; human oral absorption has not been measured
- Organ lesions: liver, pancreas, heart (reviewed in animal models)
- Cardiac tissue protection: full-length Tβ4 aided repair after coronary artery ligation (mouse model)
- Skin and corneal wound healing (rodent models)
- Hair growth: reported in normal and aged rodents given full-length Tβ4
- Scar and fibrosis reduction in wounds (animal data, reviewed)
Sources & References
The Bottom Line
- BPC-157 has preclinical (animal) data for gut lesions and tendon healing
- Thymosin beta-4 (TB-500's parent protein) has preclinical data for cardiac repair in mice and skin and corneal wound healing in rodents
- Limited human data: PMID 34324435 — a retrospective chart review of 17 patients with multiple types of knee pain, 16 of whom were reached for phone follow-up; 11/12 given intra-articular BPC-157 alone reported significant improvement, no adverse events. The remaining patients received BPC-157 combined with TB4. No standardized outcome measures were used.
- Partly different mechanisms (BPC-157: NO-system interactions; Tβ4: actin binding and cell migration; both angiogenic in animal studies) are the theoretical case for stacking
- BPC-157 is described as a stable peptide, but human oral bioavailability has not been measured
- Human safety and tolerability data are minimal for both
- The BPC + TB stack is a common combination, but no controlled study of the combination is cited here
- Neither is FDA-approved. Both are sold as research chemicals only
- Most data comes from animal studies: the only human data cited is one small, uncontrolled knee-pain chart review (PMID 34324435), mostly BPC-157 alone plus a few patients on BPC-157 + TB4. No large controlled trial results are cited for either.
- BPC-157 was placed on FDA Category 2 list in September 2023 (nomination later withdrawn), restricting compounding access
- TB-500 is banned by WADA: tested athletes cannot use it
- Research peptide purity varies wildly: third-party testing (e.g., Janoshik) is essential
- Long-term safety data in humans is effectively nonexistent for both
Peptide Supplies on Amazon
Continue Reading
Research-Grade Peptides
Research peptides are unregulated and not approved for human use. Review each product's certificate of analysis before buying.
Browse Swiss Chems →Affiliate links support HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place. For BPC-157 and TB-500, no human study cited here establishes a dose, frequency, or cycle length.
Get the Guide: $19 (normally $29) →
The Peptide Buyer’s Playbook ($19)
This page is for educational and informational purposes only. It is not medical advice. Neither BPC-157 nor TB-500 is FDA-approved for human use. Both are sold as research chemicals only. BPC-157 was placed on the FDA's Category 2 bulk drug substances list in September 2023, effectively blocking compounding pharmacy production; FDA's current list shows that nomination as withdrawn. TB-500 is banned by WADA and most sporting organizations. Most published research is preclinical (animal studies) — no large controlled human trial results are cited here for either compound. Dosing information reflects research protocols, not medical recommendations. Research peptide purity and identity are not guaranteed by vendors. Always consult a qualified healthcare provider. HighPeptides does not sell peptides or endorse their use outside of legitimate research settings.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.